Skip to main content
Premium Trial:

Request an Annual Quote

Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test

NEW YORK – Cancer detection firm Grail said Tuesday that it has entered an agreement with Quest Diagnostics for phlebotomy services in support of Galleri, Grail's multi-cancer early detection blood test.

Under the agreement, Secaucus, New Jersey-based Quest will use its phlebotomy network, which comprises roughly 2,200 patient service centers and 5,000 mobile phlebotomists, to help Menlo Park, California-based Grail with specimen collection when it launches the test this year.

Grail said in January that it expects to bring Galleri to market in the second quarter, following its PATHFINDER multi-site interventional study.

"Today, the majority of cancers go undetected until too late when outcomes are often deadly, and we believe Galleri could offer a unique and potentially life-saving solution by finding multiple types of cancers earlier," Joshua Ofman, Grail's chief medical officer and head of external affairs, said in a statement. "Our agreement with Quest will help us support convenient access to blood collection for patients and healthcare providers."

"Quest Diagnostics is committed to providing the broadest access to diagnostic innovation. That includes multi-cancer early detection, an important area of oncology diagnostics with potential to radically improve cancer screening, monitoring, and treatment," said Kristi Dolan, VP and general manager of Quest's oncology clinical franchise. "Galleri is a pioneer in early detection innovation, and we are eager to support Grail’s efforts to make it accessible to patients across the United States."

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.